Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 558, pseudogene (RNU6-558P), is a member of the U6 small nuclear RNA pseudogenes. U6 snRNA is a critical RNA component of the spliceosome, the complex responsible for removing introns from pre-mRNA in eukaryotes[3][5]. However, this specific entry, RNU6-558P, is a *pseudogene*, meaning it is a non-functional, non-protein-coding copy derived from the parental U6 snRNA gene. Pseudogenes were historically seen as "junk DNA," but more recent research indicates that some pseudogenes may have regulatory functions at the RNA level—such as binding microRNAs or RNA-binding proteins—even if most remain functionally silent in normal physiology[4][8]. There is currently no evidence for a direct therapeutic, biomarker, or pharmacological role for RNU6-558P, nor is it considered an actionable or canonical target in drug discovery[1]. Therefore, it should not be considered a therapeutic target. **Notes and explanation:** - RNU6-558P does not encode a functional protein or RNA; it is not a receptor, enzyme, transporter, or canonical drug target[1][3][5]. - The "is_incorrect" attribute is true because it is not a therapeutic target, is non-coding, and is likely included due to confusion with functional targets, thus making it a misleading or incorrect entry in the context of target-based drug discovery. - While some pseudogenes can exert regulatory functions, such activities are generally locus- and context-specific, and no such roles are documented for RNU6-558P specifically[4][8]. - If detailed structured data is needed for an actionable target or biomarker, RNU6-558P should be omitted.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 558, pseudogene (RNU6-558P).